IMAC (IMAC) Short Interest Ratio & Short Volume

Short interest is the volume of IMAC shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 82,100 shares of IMAC short. 0.40% of IMAC's shares are currently sold short. Learn More on IMAC's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.40% of IMAC's floating shares are currently sold short.

IMAC saw a increase in short interest in July. As of July 15th, there was short interest totaling 82,100 shares, an increase of 78.1% from the previous total of 46,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

IMAC currently has issued a total of 26,485,000 shares. Some of IMAC's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. IMAC currently has a public float of 20,450,000 shares.

0.40% of IMAC's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to IMAC: Pasithea Therapeutics Corp. (19.04%), Windtree Therapeutics, Inc. (8.89%), RedHill Biopharma Ltd. (2.09%), Sunshine Biopharma, Inc. (3.78%), Quoin Pharmaceuticals, Ltd. (0.26%), Mustang Bio, Inc. (3.10%), Aptose Biosciences Inc. (3.30%), InMed Pharmaceuticals Inc. (6.12%), T2 Biosystems, Inc. (6.78%), NanoVibronix, Inc. (13.35%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.50 billion), KLA Co. ($2.53 billion), Lucid Group, Inc. ($2.50 billion), T. Rowe Price Group, Inc. ($1.91 billion), Williams-Sonoma, Inc. ($1.78 billion), Coinbase Global, Inc. ($1.78 billion), HP Inc. ($1.75 billion), Rivian Automotive, Inc. ($1.70 billion), Lumen Technologies, Inc. ($1.58 billion), and Chesapeake Energy Co. ($1.45 billion). View all of the most shorted stocks.

Short selling IMAC is an investing strategy that aims to generate trading profit from IMAC as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for IMAC occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IMAC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMAC, twice per month. The most recent reporting period available is July, 15 2022.